C-Reactive Protein Levels and Outcomes after Statin Therapy

Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene·2005·New England Journal of Medicine
DOI 10.1056/nejmoa042378

Cited by (1,000)

Items 101–200 of 1,000

  1. An Assessment of Incremental Coronary Risk Prediction Using C-Reactive Protein and Other Novel Risk Markers
    Aaron R. Folsom, Lloyd E. Chambless, Christie Mitchell Ballantyne, Josef Coresh, Gerardo M HEISS, Kenneth K. Wu, Eric Boerwinkle, Thomas H. Mosley, Paul D. Sorlie, Guoqing Diao et al. · 2006 · Archives of Internal Medicine
  2. Acute-Phase Serum Amyloid A: An Inflammatory Adipokine and Potential Link between Obesity and Its Metabolic Complications
    Rongze Yang, Mi‐Jeong Lee, Hong Hu, Toni I. Pollin, Alice S. Ryan, Barbara J. Nicklas, Søren Snitker, Richard B. Horenstein, Kristen Hull, Nelson H. Goldberg et al. · 2006 · PLoS Medicine
  3. Treatment of periodontitis improves the atherosclerotic profile: a systematic review and meta‐analysis
    Wijnand J. Teeuw, Dagmar Else Slot, Hendri Susanto, Victor E. A. Gerdes, Frank Abbas, Francesco D’Aiuto, John J.P. Kastelein, Bruno G. Loos · 2013 · Journal Of Clinical Periodontology
  4. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study
    A. C. Morton, Alexander M.K. Rothman, John Pierre Greenwood, Julian P. Gunn, Alexander J. Chase, Bernard Clarke, Alistair S. Hall, Keith A.A. Fox, Claire E Foley, WINSTON A. S. BANYA et al. · 2014 · European Heart Journal
  5. Cardiac cachexia: A systematic overview
    Stephan von Haehling, Mitja Lainščak, Jochen Springer, Stefan D. Anker · 2008 · Pharmacology & Therapeutics
  6. Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome
    Stephen James Nicholls, John J.P. Kastelein, Gregory G. Schwartz, Dianna Bash, Robert S. Rosenson, Matthew Aaron Cavender, Danielle M. Brennan, Wolfgang Köenig, J. Wouter Jukema, Vijay Nambi et al. · 2014 · JAMA
  7. Arterial Stiffness Is Related to Systemic Inflammation in Essential Hypertension
    Azra Mahmud, John Feely · 2005 · Hypertension
  8. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study
    Nicholas John Timpson, Debbie A. Lawlor, Roger M. Harbord, Tom R. Gaunt, Ian N.M. Day, Lyle John Palmer, Andrew Tym Hattersley, Shah B J Ebrahim, Gordon D O Lowe, Ann Rumley et al. · 2005 · The Lancet
  9. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
    Jeffrey L. Anderson, Cynthia D. Adams, Elliott Marshall Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin et al. · 2011 · Circulation
  10. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT
    Bohula, Erin A., Giugliano, Robert P., Cannon, Christopher P., Zhou, Jing, Murphy, Sabina A., White, Jennifer A., Tershakovec, Andrew M., Blazing, Michael A., Braunwald, Eugene · 2015 · Circulation
  11. Acute Coronary Syndromes: Diagnosis and Management, Part II
    Amit Kumar, Christopher Paul Cannon · 2009 · Mayo Clinic Proceedings
  12. C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients
    Sotirios Tsimikas, James T. Willerson, Paul M. Ridker · 2006 · Journal of the American College of Cardiology
  13. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions
    Savoia, Carmine, Schiffrin, Ernesto L. · 2007 · Clinical Science
  14. Polymorphisms within the C-Reactive Protein (CRP) Promoter Region Are Associated with Plasma CRP Levels
    Christopher S. Carlson, Shelley Force Aldred, Philip Kenneth Lee, Russell P. Tracy, Stephen M. Schwartz, Mark J. Rieder, Kiang Liu, O. Dale Williams, Carlos Iribarren, E. Cora Lewis et al. · 2005 · The American Journal of Human Genetics
  15. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy
    Koenig, Wolfgang · 2013 · International Journal of Cardiology
  16. C-reactive protein, inflammation and coronary heart disease
    Amit Kumar Shrivastava, Harsh Vardhan Singh, Arun Raizada, Sanjeev Kumar Singh · 2014 · The Egyptian Heart Journal
  17. Inflammation in Atherosclerosis—No Longer a Theory
    Peter Libby · 2020 · Clinical Chemistry
  18. Anti-inflammatory therapeutics for the treatment of atherosclerosis
    Israel F. Charo, Rebecca A. Taub · 2011 · Nature Reviews Drug Discovery
  19. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin
    Paul M. Ridker · 2016 · European Heart Journal
  20. Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial
    David A. Morrow, James A. de Lemos, Marc Steven Sabatine, Stephen D. Wiviott, Michael A. Blazing, Amy M. Shui, Nader Rifai, Robert M. Califf, Eugene Braunwald M. D · 2006 · Circulation
  21. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement
    Nathan D. Wong, Matthew Jay Budoff, Keith C. Ferdinand, Ian M Graham, Erin D. Michos, Tina K. Reddy, Michael D. Shapiro, Peter Paul Toth · 2022 · American Journal of Preventive Cardiology
  22. Are Curcuminoids Effective C-Reactive Protein-Lowering Agents in Clinical Practice? Evidence from a Meta-Analysis
    Amirhossein Sahebkar · 2013 · Phytotherapy Research
  23. Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary Atherosclerotic Plaque as Assessed by Optical Coherence Tomography
    Kenichi Komukai, Takashi Kubo, Hironori Kitabata, Yoshiki Matsuo, Yuichi Ozaki, Shigeho Takarada, Yasushi Okumoto, Yasutsugu Shiono, Makoto Orii, Kunihiro Shimamura et al. · 2014 · Journal of the American College of Cardiology
  24. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis
    Pearle, A.D., Scanzello, C.R., George, S., Mandl, L.A., DiCarlo, E.F., Peterson, M., Sculco, T.P., Crow, M.K. · 2007 · Osteoarthritis and Cartilage
  25. Biomarkers in acute myocardial infarction
    Daniel Chan, Leong L. Ng · 2010 · BMC Medicine
  26. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
    Christopher Paul Cannon, Robert Patrick Giugliano, Michael A. Blazing, Robert A. Harrington, John L. Peterson, Christine McCrary Sisk, John T. Strony, Thomas A. Musliner, Carolyn H. McCabe, Enrico P. Veltri et al. · 2008 · American Heart Journal
  27. Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
    Qian Zhou, James K. Liao · 2009 · Current Pharmaceutical Design
  28. The Role of Statins in Cancer Therapy
    Katja Hindler, Charles S. Cleeland, Edgardo Rivera, Charles D. Collard · 2006 · The Oncologist
  29. Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
    Joe M. Chehade, Margaret Gladysz, Arshag D. Mooradian · 2013 · Drugs
  30. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
    Konstantinos C. Koskinas, Stephan Windecker, Giovanni Pedrazzini, Christian Eugen Mueller, Stéphane Cook, Christian M. Matter, Olivier Müller, Jonas Dominik Häner, Bariş Gencer, Carmela Crljenica et al. · 2019 · Journal of the American College of Cardiology
  31. Inflammatory and Cholesterol Risk in the FOURIER Trial
    Bohula, Erin A., Giugliano, Robert P., Leiter, Lawrence A., Verma, Subodh, Park, Jeong-Gun, Sever, Peter S., Lira Pineda, Armando, Honarpour, Narimon, Wang, Huei, Murphy, Sabina A. et al. · 2018 · Circulation
  32. Inflammation, C‐Reactive Protein, and Atherothrombosis
    Paul M. Ridker, Josh D. Silvertown · 2008 · Journal of Periodontology
  33. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
    Pradhan, Aruna D., Aday, Aaron W., Rose, Lynda M., Ridker, Paul M · 2018 · Circulation
  34. The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes
    Kausik Kumar Ray, Christopher Paul Cannon · 2005 · Journal of the American College of Cardiology
  35. Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease
    Donald M. Lloyd‐Jones, Kiang Liu, Lü Tian, Philip Greenland · 2006 · Annals of Internal Medicine
  36. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
    Jeffrey L. Anderson, Cynthia D. Adams, Elliott Marshall Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin et al. · 2013 · Circulation
  37. C‐Reactive Protein (CRP)‐Lowering Agents
    Kailash Prasad · 2006 · Cardiovascular Drug Reviews
  38. Distribution of C-Reactive Protein Values in the United States
    Steven Woloshin, Lisa M. Schwartz · 2005 · New England Journal of Medicine
  39. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
    Ridker, Paul M · 2019 · Circulation Research
  40. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)
    Paul M. Ridker · 2009 · Journal of Thrombosis and Haemostasis
  41. Chocolate and Prevention of Cardiovascular Disease: A Systematic Review
    Eric L. Ding, Susan M. Hutfless, Xin Ding, Saket R. Girotra · 2006 · Nutrition & Metabolism
  42. Novel biomarkers for cardiovascular risk prediction.
    Juan Wang, Guo-Juan Tan, Li-Na Han, Yongyi Bai, Miao He, Hongbin Liu · 2017 · Europe PMC (PubMed Central)
  43. Early Inflammation and Risk of Long-Term Development of Heart Failure and Mortality in Survivors of Acute Myocardial Infarction
    Suleiman, Mahmoud, Khatib, Rania, Agmon, Yoram, Mahamid, Riad, Boulos, Monther, Kapeliovich, Michael, Levy, Yishai, Beyar, Rafael, Markiewicz, Walter, Hammerman, Haim et al. · 2006 · Journal of the American College of Cardiology
  44. Inflammation and ischaemic stroke
    Keith W. Muir, Pippa J. Tyrrell, Naveed A. Sattar, Elizabeth A. Warburton · 2007 · Current Opinion in Neurology
  45. Combination therapy of statin with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers in patients after myocardial infraction (MI)
    Naruszewicz, Marek, Łaniewska, Iwona, Millo, Barbara, Dłużniewski, Mirosław · 2007 · Atherosclerosis
  46. The natural history of chronic obstructive pulmonary disease
    David M. Mannino, Graham C. M. Watt, David J. Hole, Charles R Gillis, CL Hart, Alex McConnachie, George Davey Smith, Mark N. Upton, Victor M Hawthorne, Don D. Sin et al. · 2006 · European Respiratory Journal
  47. Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training
    Nicklas, B. J. · 2005 · Canadian Medical Association Journal
  48. Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study
    Stefan Blankenberg, Matthew McQueen, Marek Smieja, Janice Pogue, Cynthia M. Balion, Eva Lonn, Hans J. Rupprecht, Christoph Bickel, Laurence Tiret, François Cambien et al. · 2006 · Circulation
  49. Cardiovascular Disease in COPD
    John D. Maclay, William MacNee · 2013 · CHEST Journal
  50. Innate Immune Cells in Liver Inflammation
    Evaggelia Liaskou, Daisy V. Wilson, Ye Htun Oo · 2012 · Mediators of Inflammation
  51. High-Sensitivity C-Reactive Protein, Lipoprotein-Associated Phospholipase A2, and Outcome After Ischemic Stroke
    Mitchell S.V. Elkind, Wanling Tai, Kristen Coates, Myunghee Cho Paik, Ralph L. Sacco · 2006 · Archives of Internal Medicine
  52. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism
    Robert Caesar, Frida Fåk, Fredrik Bäckhed · 2010 · Journal of Internal Medicine
  53. Statins Exert Endothelial Atheroprotective Effects via the KLF2 Transcription Factor
    Kush M. Parmar, Vinod E. Nambudiri, Guohao Dai, H. Benjamin Larman, Michael A. Gimbrone, Guillermo García‐Cardeña · 2005 · Journal of Biological Chemistry
  54. Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes: New Evidence for Direct Antiinflammatory Effects of Statins
    Arnaud, Claire, Burger, Fabienne, Steffens, Sabine, Veillard, Niels R., Nguyen, Tuan Huy, Trono, Didier, Mach, François · 2005 · Arteriosclerosis, Thrombosis, and Vascular Biology
  55. Chronic Stable Angina
    Jonathan Abrams · 2005 · New England Journal of Medicine
  56. Physical Activity and High-Sensitivity C-Reactive Protein
    Eric P. Plaisance, Peter W. Grandjean · 2006 · Sports Medicine
  57. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
    Daniel M. Bloomfield, Gary L. Carlson, Aditi Sapre, Diane L. Tribble, James M. McKenney, Thomas W Littlejohn, Christine McCrary Sisk, Yale Mitchel, Richard C. Pasternak · 2008 · American Heart Journal
  58. Non-adherence to cardiovascular medications
    Kumaran Kolandaivelu, Benjamin B. Leiden, Patrick T. O’Gara, Deepak L. Bhatt · 2014 · European Heart Journal
  59. Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer
    Alawi A.A. Alsheikh-Ali, Prasad V. Maddukuri, Hui Han, Richard H. Karas · 2007 · Journal of the American College of Cardiology
  60. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
    Thimoteus Speer, Stefanie Dimmeler, Stefan J. Schunk, Danilo Fliser, Paul M. Ridker · 2022 · Nature Reviews Nephrology
  61. Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l
    Paul M. Ridker, David A. Morrow, Lynda M. Rose, Nader Rifai, Christopher Paul Cannon, Eugene Braunwald M. D · 2005 · Journal of the American College of Cardiology
  62. Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
    Alan Chait, Chang Yeop Han, John F. Oram, Jay W. Heinecke · 2005 · Journal of Lipid Research
  63. The molecular mechanisms of the thrombotic complications of atherosclerosis
    Peter Libby · 2008 · Journal of Internal Medicine
  64. Gender-specific care of the patient with diabetes: review and recommendations
    Legato, Marianne J., Gelzer, Andrea, Goland, Robin, Ebner, Susana A., Rajan, Sabitha, Villagra, Victor, Kosowski, Mark · 2006 · Gender Medicine
  65. Lipoprotein-Associated Phospholipase A 2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial
    Michelle L. O’Donoghue, David A. Morrow, Marc Steven Sabatine, Sabina A. Murphy, Carolyn H. McCabe, Christopher Paul Cannon, Eugene Braunwald M. D · 2006 · Circulation
  66. Acute Coronary Syndrome
    Benjamin M. Scirica · 2010 · Journal of the American College of Cardiology
  67. Evidence for Statin Pleiotropy in Humans
    Ping‐Yen Liu, Yen-Wen Liu, Li-Jen Lin, Jyh-Hong Chen, James K. Liao · 2008 · Circulation
  68. Rapid, Direct Effects of Statin Treatment on Arterial Redox State and Nitric Oxide Bioavailability in Human Atherosclerosis via Tetrahydrobiopterin-Mediated Endothelial Nitric Oxide Synthase Coupling
    Antoniades, Charalambos, Bakogiannis, Constantinos, Leeson, Paul, Guzik, Tomasz J., Zhang, Mei-Hua, Tousoulis, Dimitris, Antonopoulos, Alexios S., Demosthenous, Michael, Marinou, Kyriakoula, Hale, Ashley et al. · 2011 · Circulation
  69. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
    Shapiro, Michael D., Fazio, Sergio · 2016 · Circulation Research
  70. Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein
    Paul M. Ridker, Jean G. MacFadyen, Michael D. Cressman, Robert J. Glynn · 2010 · Journal of the American College of Cardiology
  71. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)—Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention?
    Samia Mora, Paul M. Ridker · 2005 · The American Journal of Cardiology
  72. The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery
    Yannick Le Manach, Gilles Godet, Pierre Coriat, Claire Martinon, Michèle Bertrand, Marie Hélène Fléron, Bruno Riou · 2007 · Anesthesia & Analgesia
  73. The novel role of C-reactive protein in cardiovascular disease: Risk marker or pathogen
    Andrew Wilson, Marno Celeste Ryan, Andrew Boyle · 2005 · International Journal of Cardiology
  74. Impact of Physical Activity, Cardiorespiratory Fitness, and Exercise Training on Markers of Inflammation
    Carl J. Lavie, Timothy S. Church, Richard V. Milani, Conrad P. Earnest · 2011 · Journal of Cardiopulmonary Rehabilitation and Prevention
  75. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease
    Ridker, Paul M · 2009 · Clinical Chemistry
  76. Periodontitis and risk for atherosclerosis: an update on intervention trials
    Maurizio S. Tonetti · 2009 · Journal Of Clinical Periodontology
  77. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects.
    Yasuda, H., Yuen, P.S.T., Hu, X., Zhou, H., Star, R.A. · 2006 · Kidney International
  78. The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent
    Emile R. Mohler, Christie Mitchell Ballantyne, Michael H. Davidson, M Hanefeld, Luis Miguel Ruilope, Joel L. Johnson, Andrew A. Zalewski · 2008 · Journal of the American College of Cardiology
  79. Inflammatory response is associated with aortic dissection
    Fang Luo, Xianliang Zhou, Jian‐Jun Li, Rutai Hui · 2008 · Ageing Research Reviews
  80. High-Sensitivity C-Reactive Protein and Coronary Heart Disease in a General Population of Japanese
    Hisatomi Arima, Michiaki Kubo, Koji Yonemoto, Yasufumi Doi, Toshiharu Ninomiya, Yumihiro Tanizaki, Jun Hata, Kiyoshi Matsumura, Mitsuo Iida, Yutaka Kiyohara · 2008 · Arteriosclerosis Thrombosis and Vascular Biology
  81. Inflammation and Atherothrombosis
    Peter Libby, Paul M. Ridker · 2006 · Journal of the American College of Cardiology
  82. Inflammation and Atherosclerosis—Revisited
    Sadip Pant, Abhishek J. Deshmukh, Guru S. GuruMurthy, Naga Venkata K. Pothineni, Thomas Evans Watts, Francesco Romeo, Jawahar L. Mehta · 2013 · Journal of Cardiovascular Pharmacology and Therapeutics
  83. FGF23 Actions on Target Tissues—With and Without Klotho
    Beatrice Richter, Christian Faul · 2018 · Frontiers in Endocrinology
  84. Effect of Colchicine (0.5 mg Twice Daily) on High-Sensitivity C-Reactive Protein Independent of Aspirin and Atorvastatin in Patients With Stable Coronary Artery Disease
    Mark Nidorf, Peter Lindsay Thompson · 2007 · The American Journal of Cardiology
  85. How Common Is Residual Inflammatory Risk?
    Ridker, Paul M · 2017 · Circulation Research
  86. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis
    Bruce E Strober, Craig F. Teller, Paul Steven Yamauchi, Jeffrey L. Miller, M. Hooper, Y-C. Yang, Frank J. Dann · 2008 · British Journal of Dermatology
  87. Detection and Treatment of Vulnerable Plaques and Vulnerable Patients
    Sergio Waxman, Fumiyuki Ishibashi, James E. Muller · 2006 · Circulation
  88. Correlation of Peripheral-Blood Gene Expression With the Extent of Coronary Artery Stenosis
    James A. Wingrove, Susan E. Daniels, Amy J. Sehnert, Whittemore G. Tingley, Michael R. Elashoff, Steven J. Rosenberg, Lutz Buellesfeld, Eberhard Grube, Laura Kristin Newby, Geoffrey S. Ginsburg et al. · 2008 · Circulation Cardiovascular Genetics
  89. High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation
    Gregory Y.H. Lip, Jeetesh V. Patel, Elizabeth Hughes, Robert G. Hart · 2007 · Stroke
  90. Selective Inhibition of PI3K/Akt/mTOR Signaling Pathway Regulates Autophagy of Macrophage and Vulnerability of Atherosclerotic Plaque
    Chungang Zhai, Jing Cheng, Haroon Mujahid, Hefeng Wang, Jing Kong, Yue Yin, Jifu Li, Yun Liang Zhang, Xiaoping Ji, Wenqiang Chen · 2014 · PLoS ONE
  91. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease
    Kyle A. Nelson, Valentı́n Fuster, Paul M. Ridker · 2023 · Journal of the American College of Cardiology
  92. Innate and adaptive immunity in atherosclerosis
    René R. Sevag Packard, Andrew H. Lichtman, Peter Libby · 2009 · Seminars in Immunopathology
  93. The Verdict Is Still Out
    Benjamin M. Scirica, David A. Morrow · 2006 · Circulation
  94. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation
    George S. Abela · 2010 · Journal of clinical lipidology
  95. Effect of CC Chemokine Receptor 2 CCR2 Blockade on Serum C-Reactive Protein in Individuals at Atherosclerotic Risk and With a Single Nucleotide Polymorphism of the Monocyte Chemoattractant Protein-1 Promoter Region
    Jim Gilbert, Julie A. Lekstrom-Himes, Debra D. Donaldson, Yih Lee, Mingxiu Hu, Jing Xu, Timothy L. Wyant, Michael H. Davidson · 2011 · The American Journal of Cardiology
  96. C-reactive protein: a nontraditional serum marker of cardiovascular risk
    Sarah D. de Ferranti, Nader Rifai · 2007 · Cardiovascular Pathology
  97. Interferon-α effects on diurnal hypothalamic–pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior
    Raison, C L, Borisov, A S, Woolwine, B J, Massung, Breanne, Vogt, G, Miller, A H · 2010 · Molecular Psychiatry
  98. Effect of Intensive Versus Moderate Lipid-Lowering Therapy on Epicardial Adipose Tissue in Hyperlipidemic Post-Menopausal Women
    Nikolaos A. Alexopoulos, Bekir H. Melek, Chesnal Dey Arepalli, Gregory Randell Hartlage, Zhengjia Chen, Sungjin Kim, Arthur E. Stillman, Paolo Raggi · 2013 · Journal of the American College of Cardiology
  99. High Attributable Risk of Elevated C-Reactive Protein Level to Conventional Coronary Heart Disease Risk Factors
    Michael J. Miller, Min Zhan, Stephen Havas · 2005 · Archives of Internal Medicine
  100. Pleiotropic effects of statins
    Hardik Vasnawala, Narasaraju Kavalipati, Jay Shah, Ananthraman Ramakrishan · 2015 · Indian Journal of Endocrinology and Metabolism